Kornimate/medical-research-clean huggingface dataset:
development of standard references of maximal inspiratory pressure and maximal expiratory pressure in healthy adults

Conditions: Healthy Adults

Summary: (1) maximum respiratory pressure (mrp)1) maximum inspiratory pressure (maximum intake pressure) and maximum expiratory pressure (mep) digital spirometer (pony fx, cosmed inc., italy) are used to measure the micro-paste in a seated position. mip is based on the pressure maintained for at least 1 second, inhaling or exhaling with maximum effort in the maximum exhalation state (=residual volume) and the maximum exhalation state (=total lung capacity). the maximum positive pressure value of the mep and the minimum sound pressure value of the mip are selected among the three or more attempts. 2) using the mvv (maximum volitional ventilation) digital spirometer (pony fx, cosmed inc., italy) machine, repeat breathing deeply and quickly for 12 seconds while wearing a nose plug, and multiply it by 5 to obtain the l/min value. (2) measure the values of the pneumatic ventilation. · fvc (forced vital capacity): total expiratory volume of one of the maximum effort gases · fev1 (forced expiratory volume 1, effort expiratory volume): ejected expiratory volume of the first second of the maximum effort expiratory volume (fev1/fvc): fvc ratio, percentage of fvcs, and extraction of the fvc (excessive flow). pef): highest speed of effort opportunity


Eligibility criteria:
inclusion criteria: 1. 19 to 65 years old. 2. a patient under general anesthesia 3. patients in asa class i to ii 4. a patient with no history of thoracic anatomy or surgery 5. patients with normal chest x-ray findings for preoperative evaluation. exclusion criteria: 1. patients with no natural history of thoracic abnormalities or surgery 2. patients with asthma, pneumonia, tuberculosis, pneumothorax, chronic obstructive pulmonary disease and epileptic pulmonary disease 3. patients who have difficulty communicating with the examiner.
open pilot trial of adapted cognitive processing therapy for comorbid ptsd and opioid use disorder

Conditions: Posttraumatic Stress Disorder (PTSD); Opioid Use Disorder

Summary: the goal of this open pilot trial is to learn if an adapted version of cognitive processing therapy (cpt), delivered through telehealth, can treat posttraumatic stress disorder (ptsd) in adults who use syringe services programs. the main questions it aims to answer are: * can the intervention be done in syringe services programs? * are syringe services program clients and staff open to the intervention? * can the intervention lower ptsd symptoms and help participants keep taking their medication for opioid use disorder (ex. buprenorphine or methadone)? participants will: * attend 4-18 tele-delivered cpt sessions at the syringe services program * complete between-session cpt practice with the support of ssp-based "coaches" * meet with research staff monthly to complete surveys of their ptsd symptoms, drug use, and mental health


Eligibility criteria:
inclusion criteria: * over the age of 18 * regular syringe services program attendance (ex. at least 4 visits in the past month) * meeting dsm-5 opioid use disorder criteria * having been prescribed a medication for opioid use disorder in the past 30 days at the time of screening * criterion a event as measured by the life events checklist for dsm-5 (lec-5) * ptsd symptoms at the level of a ptsd diagnosis as evidenced by a score of 31 or greater on the ptsd checklist for dsm-5 (pcl-5) * ability to understand english * consent to have assessment interviews audio recorded and teletherapy sessions video recorded for research purposes * ability to provide informed consent exclusion criteria: * high risk for suicidal thoughts and/or behaviors that would make participation dangerous, as measured by the columbia suicide severity rating scale lifetime-recent screen * meeting dsm-5 criteria for a current psychotic or bipolar disorder. * cognitive impairment liable to interfere with completion of study procedures * currently receiving trauma-focused psychotherapy (i.e. prolonged exposure, cognitive processing therapy).
prophylactic negative pressure wound therapy in laparotomy wounds: a randomized clinical trial

Conditions: Wound; Infection Prevention; Negative Pressure Wound Therapy

Summary: total 70 participants meeting selection criteria will be enrolled in the study from operational theatre. they will be randomly divided in two groups by using lottery method. in group a, negative pressure wound therapy will be applied at end of procedure. in group b, no negative pressure wound therapy will be placed. they will be shifted to post-surgical wad for 72 hours and then will be discharged with prescription of standard antibiotics and will be followed-up in opd for 30 days. if patient will develop surgical site wound infection, then it will be noted. if infection will not be cured with antibiotics course, then re-operation will be done. patients complications will be managed as per hospital protocol. all this information will be recorded in proforma.


Eligibility criteria:
inclusion criteria: * patients of age between 20 to 70 years, both genders * undergoing laparotomy under general anaesthesia * asa i-ii exclusion criteria: * patients who did not complete the follow up instructions * pregnant patients * patients already undergone a relook laparotomy, if their abdomen is left open or if unable to adhere
expanded access to provide suvn-502 for the treatment of subjects with alzheimer's disease

Conditions: Alzheimer Disease; Dementia; Cognition Disorders

Summary: this is an expanded access program (eap) for eligible participants. this program is designed to provide access to suvn-502 for the treatment of alzheimer's disease. investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. subjects will not be evaluated for efficacy and safety during the expanded access.


Eligibility criteria:
inclusion criteria: * subjects who have completed the 30 week treatment period of study ctp2s1502ht6 as planned and wish to continue treatment with suvn-502. * subject (or subject's legally acceptable representative) and caregiver must sign the informed consent form (icf) to participate in the study. exclusion criteria: * has participated or is participating in any other clinical (investigational) study after completion of ctp2s1502ht6 study. * is treated or likely to require treatment during the study with any medication prohibited by this expanded access program.

Keywords: suvn-502 expanded access
inflammatory bowel disease registry in daegu-gyeongbuk

Conditions: Idiopathic Chronic Inflammatory Bowel Disease

Summary: the purpose of this study is to investigate the incidence and natural course of inflammatory bowel disease in the southeastern area of korea.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of inflammatory bowel disease including crohn's disease and ulcerative colitis * followed up for at least 6 months for the correct diagnosis exclusion criteria: * patients who do not live in daegu-gyeongbuk province

Keywords: inflammatory bowel disease, registry, incidence, korea
low vision study comparing ev training vs. cctv for amd rehabilitation

Conditions: AMD

Summary: patients with advanced age-related macular degeneration will be randomized into one of two treatment groups. one group will receive eccentric view (ev) training while the other a closed circuit television (cctv) training for 6 weeks. reading speed and accuracy will be assessed pre- and post- treatment to determine if one treatment is superior to the other.

age-related macular degeneration is the single most common cause of visual impairment in canada, affecting people over the age of 55 years. it causes loss of central, detailed vision, resulting in difficulty with fine vision tasks, such as reading and writing. at present there is no fully effective prevention or treatment for this condition, but people do benefit from visual rehabilitation. two of the most common rehabilitation techniques are eccentric viewing training and an electronic magnification system called a closed circuit television (cctv). in eccentric viewing training the person is taught to use his or her remaining side vision, instead of central vision. the cctv provides high levels of magnification to compensate for the loss of detail vision. the purpose of this randomized clinical trial is to compare the effectiveness of these two interventions. in the study people will be randomly assigned to either receiving eccentric viewing training or a cctv. this will happen after they have received basic, optical low vision services and training through the cnib. we will assess their performance with either the cctv or ev training with a variety of reading tasks and questionnaires. the results will give evidence for how it is most beneficial to use resources and as such will be very important in future planning of low vision services. hypothesis: eccentric viewing training will improve reading speed over cctv by at least 10 words per minute in patients with advanced amd.

Eligibility criteria:
inclusion criteria: * first time amd patient sent to cnib for visual rehabilitation * macular degeneration reducing visual acuity (va) to between 20/160 and 20/400 (etdrs scale) * over the age of 50 years * english as the first language and able to read exclusion criteria: * expected anti-vegf or visudyne treatment over the course of the study * individuals who do not have reading as a life goal * mental cognition that makes learning the specific rehabilitation tasks unlikely (determined by mini-mental state exam) * any other ocular pathology that can reduce central vision including cornea decompensation (scar or thickness), cataract (grade iii or more for each type of cataract), vitritis (2+ or more) or advanced glaucoma (c/d ratio of \>0.7)

Keywords: amd ev cctv reading vision
duration of brace wear in clubfoot treatment - a prospective randomized trial

Conditions: Isolated Clubfoot

Summary: the goal of this multi-center, randomized, controlled trial is to evaluate the effectiveness of a 2 year versus 4 year bracing protocol in preventing isolated clubfoot recurrence within the first year post-treatment, and to evaluate factors associated with recurrence in isolated clubfoot.

the study is based on the hypothesis that prolonged bracing will reduce clubfoot recurrence. in addition to bracing length, the study will determine if other factors in addition to duration of brace wear are associated with recurrence.

Eligibility criteria:
inclusion criteria: * subject \< 1 year of age when treatment initiated at local site * confirmed diagnosis of isolated clubfoot * at least one foot demonstrates fixation of the foot in equinus, forefoot adduction, cavus and hindfoot varus * deformity was present at birth exclusion criteria: * previous foot abduction bracing * previous surgical correction (excluding tenotomy) * dysmorphic features, additional anomalies (i.e. congenital heart disease, hypospadias, a genetic syndrome), or developmental delay * neurologic cause for clubfoot (i.e. myelomeningocele or sacral agenesis)
a trial of shr-1316/placebo in combination with chemotherapy in patients with resectable nsclc

Conditions: Non-Small-Cell Lung Cancer

Summary: this trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody shr-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable stage ii, iiia, or selected iiib non-small cell lung cancer (nsclc) followed by adjuvant shr-1316 or placebo and monitoring.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status 0 or 1 * have previously untreated, pathologically confirmed resectable stage ii, iiia, or selected iiib nsclc. staging should be based on the 8th edition of the ajcc/uicc staging system * evaluation by an attending thoracic surgeon to confirm eligibility for an r0 resection with curative intent * adequate tumor tissue sample blocks for central programmed death-ligand 1 (pd-l1) testing * measurable disease as defined by recist v1.1 * adequate organ function * women of childbearing age without sterilizing or male, must agree to use contraception or practice abstinence at least 180 days after the last dose of study treatment exclusion criteria: * any previous systematic anti-cancer therapy for lung cancer * with active, known or suspected autoimmune disease of autoimmune disease * malignancies other than nsclc within 5 years prior to randomization * has or suspected has a history of pneumonitis /interstitial lung disease or any serve lung diseases which will influence the examination of lung function * significant history of cardiovascular and cerebrovascular disease * significant haemorrhagic disease * has an arteriovenous thrombotic events * has a known history of human immunodeficiency virus (hiv) infection * has a known active hepatitis b or hepatitis c * allergic to monoclonal antibodies or other protein drugs * allergic to the intervention regimens * pregnant or lactating women * has known psychiatric or substance abuse disorders * confirmed covid-19 infection or suspected covid-19 infection or close contact with a person with known or suspected covid-19 infection.
point of care testing of platelet function in patients with acute upper gastrointestinal bleeding

Conditions: Hematemesis; Melena; Gastrointestinal Hemorrhage; Platelet Dysfunction

Summary: acute upper gastrointestinal bleeding (augib) is a common medical emergency. in an ageing population, antiplatelet drugs are increasingly being prescribed for treatment and prophylaxis against cardiovascular thrombo-embolic events. in many patients, platelet dysfunction mostly acquired is the principal cause of bleeding. to clinicians, the management of patients on antiplatelet drugs or anticoagulants is a challenge. one has to carefully balance the bleeding against thrombo-embolic risks. therefore measuring platelet function should be integral in the management plan. a quantitative measurement allows titration of platelet function in accordance with bleeding or thromboembolic risk. platelet function has not been studied in a large cohort of patients with acute upper gastrointestinal bleeding. as a first step, the study will determine if platelet dysfunction is associated with clinical outcome. in this prospective, observational single centre cohort study of consecutive patients with overt signs of acute upper gastrointestinal bleeding, their platelet function by point of care tests (light transmittance aggregometry, verify now p2y12,the platelet function analysis system (pfa-100) upon their admissions. patients will be followed up for 30 days after trial enrollment. the primary endpoint is defined as significant bleeding that requires interventions (endoscopic, radiologic or surgery). secondary end points include cardio- and cerebrovascular thrombo-embolic events and all cause deaths. a receiver operating characteristic (roc) curve analysis is calculated for each point-of-care test to evaluate if individual test can distinguish between patients with and without primary end point. this study aims to evaluate the capability of platelet function tests to predict clinical outcome in patients with augib. logistic regression models will then be built in search for independent correlates to the primary and secondary endpoints and to adjust for confounding variables.


Eligibility criteria:
inclusion criteria: * patients with overt signs of acute upper gastrointestinal bleeding (melena, coffee ground or fresh hematemesis with or without circulatory instability) exclusion criteria: * asymptomatic patients with anemia are absence of positive gastroscopic findings to support gastrointestinal bleeding.
a study of ly2334737 in participants with cancer that is advanced and/or has spread

Conditions: Malignant Solid Tumor; Solid Tumor; Metastatic Tumor

Summary: the purpose of this study is to evaluate two different dosing regimens of ly2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. information about side effects will be collected.

this study will consist of a dose escalation phase (arms a and b) followed by a dose confirmation phase.

Eligibility criteria:
inclusion criteria: * diagnosis of advanced and/or metastatic cancer (including lymphoma) for which no treatment of higher priority exists * eastern cooperative oncology group (ecog) performance status ≤ 2 * estimated life expectancy of more than 12 weeks * have discontinued all previous therapies for cancer for at least 30 days (6 weeks for mitomycin-c or nitrosoureas) and recovered from acute effects of therapy * have discontinued radiotherapy more than one week before enrolling in the study and have recovered from the acute effects of therapy * have adequate organ function * follow your doctor's directions and live close enough to the study site so you can continue to go to the clinic for follow-up * are willing and able to swallow capsules and follow study procedures * have given written informed consent prior to any study-specific procedures * males and females with reproductive potential should use medically approved contraceptive precautions during the study and for 6 months following the last dose of study drug * females with child-bearing potential must have had a negative urine or serum pregnancy test 7 days prior to the first dose of study drug exclusion criteria: * have gastrointestinal diseases or prior surgery that may interfere with the absorption of medication taken by mouth * females who are pregnant or lactating * symptomatic central nervous system malignancy or metastasis * known positive test results in human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or hepatitis c antibodies (hcab) * liver cirrhosis or chronic hepatitis * acute or chronic leukemia * are currently receiving treatment with valproic acid (vpa) and its derivatives, or if you have a history of intolerance to vpa * known hypersensitivity to gemcitabine
identifying perceived barriers and facilitators toward a liver transplantation prehabilitation

Conditions: Liver Transplant; Complications

Summary: the purpose of this study is to formally identify patient and caregiver perceived needs, barriers, and facilitators to inform the development of a home-based multimodal prehabilitation program for potential lt candidates.

after being informed about the study and potential risks, all participants (patients and caregivers) giving written informed consent will be invited to participate in one of three research activities: interviews (n=10), nominal group technique meetings (n=64), or card-sorting and rating survey (n=40).

Eligibility criteria:
inclusion criteria: liver transplant (lt) candidates are: * adult esld patients (age=19-74 years) who are assigned to the lt waitlist * english-speaking * no contraindication to moderate intensity physical activities * physician clearance for participation in moderate intensity physical activities * no history of dementia or organic brain syndrome caregivers: * adult (age≥ 19 years) * english-speaking * provide direct care to lt candidates exclusion criteria: * inability to communicate verbally in english * documentation of cognitive deficits

Keywords: end-stage liver disease (esld) frailty prehabilitation
artificial saliva containing cumin and ginger extract in head and neck cancer patients with xerostomia

Conditions: Xerostomia

Summary: the objectives of this study are to evaluate efficacy and safety of artificial saliva containing cumin and ginger extract in head and neck cancer patients with xerostomia.

there are 52 patients in this study. they are divided into 2 groups which are artificial saliva containing cumin and ginger extract group (test group) 26 patients and placebo group 26 patients. the patients spray the sample into the mouth 3 times/day for 14 day. amount of saliva, ph of saliva, xerostomia questionnaires, who oral mucositis grading scale, quality of life, adverse events, and satisfaction were assessed.

Eligibility criteria:
inclusion criteria: * age more than 18 years * head and neck cancer with xerostomia * 6 months post radiation * willing to participate in this study exclusion criteria: * sialolith or sjogren's syndrome * uncontrolled cancer * using artificial saliva more than 2 weeks * taking pilocarpine or cevimeline more than 2 weeks * allergic to cumin, ginger, xylitol, and glycerin * history of other oral mucosal diseases * pregnancy and lactation
a prototype tri-modal imaging device for breast cancer

Conditions: Breast Cancer Invasive Nos; Primary Invasive Breast Cancer

Summary: breast conservation surgery (bcs) is performed on patients with breast cancer with the intent to resect and completely remove the tumour while conserving as much of the surrounding normal tissue as possible. currently, there is no way for surgeons to determine the adequacy of surgical resection in real-time during surgery; the assessment of surgical margins requires histological examination that is not available in real-time and is impractical in most clinical cases. this results in a re-excision rate of 23% among canadian women in order to achieve optimal surgical margins. in addition, the presence or absence of cancer in tumor draining lymph nodes is recognized as a key element for breast cancer staging; however, lymph node dissection can be associated with overtreatment and morbidity (nerve damage and post surgical lymphedema) and histological analysis of nodes can be time consuming and thus delay subsequent procedures. in an effort to address these issues, we have designed and constructed, in collaboration with sogang university, seoul, s. korea, a novel imaging system that performs three complementary imaging modalities (tri-modal): ultrasound (us), photoacoustic (pa) and fluorescence (fl). this first-in-human pilot study will recruit 10 breast cancer patients undergoing breast conserving surgery at princess margaret hospital (toronto, canada). the study is designed to test our tri-modal (us, pa, fl) imaging technology in breast cancer patients. the overall goal is to obtain initial information on the technical feasibility of the tri-modal system in a peri-operative setting and to confirm the anticipated safety of the procedures. additionally, it will provide initial data on the ability of this system to detect/localize primary breast cancer lesions and cancer-involved lymph nodes prior to surgery.


Eligibility criteria:
inclusion criteria: * female patients with biopsy-confirmed first primary invasive unilateral breast cancer * 18 years of age or older * have consented to standard of care surgery (lumpectomy, mastectomy) for primary invasive breast cancer, with or without auxiliary lymph node dissection * have had pre-surgical imaging of the affected breast and (where applicable) lymph notes (note: additional imaging may also be done day of scheduled surgery i.e. mammography, nuclear medicine) * have existing biopsies banked at the hospital * surgery scheduled at princess margaret hospital * tumor size of 1 cm or larger exclusion criteria: * inability to provide informed consent * pre-operative therapy for current breast cancer (including chemotherapy, endocrine therapy and radiotherapy) * history of other previous cancer requiring therapy (including chemotherapy, endocrine therapy and radiotherapy) within the past 12 months * history of photosensitivity, skin disease or recurrent disease * pregnancy * absence of in-house biopsy in tissue bank * bilateral breast cancer